EGFR and non-small cell lung carcinoma: A multicenter clinical trial [38] demonstrated that in EGFR-mutated NSCLC patients with brain metastases, first-line gefitinib treatment resulted in a median iPFS of 9.1 months and a median overall survival (OS) of 28.9 months.